ClinicalTrials.gg

Program

buntanetap

Also written as “buntanetap/posiphen”, “Posiphen” and “Buntanetap/Posiphen”.

Its studies are mostly in Alzheimer Disease · Parkinson Disease, led by Annovis Bio.

Furthest: phase 3, since Apr 19, 20227 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Annovis Bio73 open or runningphase 3since Apr 19, 2022Sep 29, 2016Dec 2027phase 3 · NCT06709014

Also a collaborator on its studies: prevail-infoworks, propharma-group, tfs-trial-form-support and parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 29, 2016First study: phase 2 study in Alzheimer DiseaseFirst studyNCT02925650 · 18 enrolled · United States
  2. Aug 11, 2020Phase 2 study in Alzheimer DiseaseNCT04524351 · 75 enrolled · United States
  3. Apr 19, 2022Phase 3 study in Parkinson DiseaseNCT05357989 · 523 enrolled · United States, Germany, Hungary and more
  4. Jan 6, 2023Phase 3 study in Alzheimer DiseaseNCT05686044 · 351 enrolled · United States
  5. Nov 26, 2024Phase 3 study in Alzheimer DiseaseNCT06709014 · 760 enrolled · United States
  6. Nov 26, 2025Phase 3 study in Parkinson DiseaseNCT07284784 · 500 planned · United States
  7. Jul 31, 2026Phase 3 study in Alzheimer DiseaseNCT07757204 · 400 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 3 study in Alzheimer DiseaseNCT06709014
  2. Sep 2029Primary completion: phase 3 study in Parkinson DiseaseNCT07284784
  3. Feb 21, 2030Primary completion: phase 3 study in Alzheimer DiseaseNCT07757204

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07757204Alzheimer Disease · United States3Not yet recruitingFeb 21, 2030400
NCT07284784Parkinson Disease · United States3RecruitingSep 2029500
NCT06709014Alzheimer Disease · United States3Active, not recruitingDec 2027760
NCT05686044Alzheimer Disease · United States3CompletedFeb 13, 2024351
NCT05357989Parkinson Disease · United States, Germany, Hungary and more3CompletedDec 4, 2023523
NCT04524351Alzheimer Disease · United States2CompletedAug 16, 202175
NCT02925650Alzheimer Disease · United States2CompletedDec 10, 202118

How it is read

Names in the registry

  • “buntanetap/posiphen”, 4 entries
  • “Posiphen”, 2 entries
  • “Buntanetap/Posiphen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
buntanetap (Annovis Bio): development program | ClinicalTrials.gg